Literature DB >> 19535443

The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity.

Nicholas M Provine1, Wendy Blay Puryear, Xueling Wu, Julie Overbaugh, Nancy L Haigwood.   

Abstract

Two frequently employed methods for generating well-characterized, genetically defined infectious human immunodeficiency virus type 1 in vitro include the use of infectious molecular clones (IMCs) and pseudoviruses (PVs) competent for single-round infection. We compared six matched pairs of IMCs and PVs. The relative amounts of Env incorporated and efficiency of cleavage differed substantially between the two systems. Altering the ratio of proviral genome and env expression plasmids can produce pseudovirions that are structurally more similar to the matched IMCs. Differences in Env incorporation and cleavage translated into moderate differences in assays infectivity and sensitivity to neutralizing antibodies and entry inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535443      PMCID: PMC2738156          DOI: 10.1128/JVI.00423-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

Authors:  M Baba; O Nishimura; N Kanzaki; M Okamoto; H Sawada; Y Iizawa; M Shiraishi; Y Aramaki; K Okonogi; Y Ogawa; K Meguro; M Fujino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.

Authors:  E Michelle Long; Stephanie M J Rainwater; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2002-05-20       Impact factor: 2.205

4.  Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties.

Authors:  M Poss; J Overbaugh
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Capture of an early fusion-active conformation of HIV-1 gp41.

Authors:  R A Furuta; C T Wild; Y Weng; C D Weiss
Journal:  Nat Struct Biol       Date:  1998-04

7.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

Authors:  B S Chapman; R M Thayer; K A Vincent; N L Haigwood
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

8.  HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity.

Authors:  Frédéric Reynard; Ahmed Fatmi; Bernard Verrier; Frédéric Bedin
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

9.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

Authors:  J M McCune; L B Rabin; M B Feinberg; M Lieberman; J C Kosek; G R Reyes; I L Weissman
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

10.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  22 in total

1.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

Review 2.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

3.  Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.

Authors:  David F Boyd; Dylan Peterson; Beth S Haggarty; Andrea P O Jordan; Michael J Hogan; Leslie Goo; James A Hoxie; Julie Overbaugh
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

4.  Measuring HIV fusion mediated by envelopes from primary viral isolates.

Authors:  Marielle Cavrois; Jason Neidleman; Nicole Galloway; Cynthia A Derdeyn; Eric Hunter; Warner C Greene
Journal:  Methods       Date:  2010-06-08       Impact factor: 3.608

5.  Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells.

Authors:  Daryl Humes; Julie Overbaugh
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

6.  Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.

Authors:  Adam S Dingens; Hugh K Haddox; Julie Overbaugh; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2017-06-01       Impact factor: 21.023

7.  Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Authors:  Ema T Crooks; Tommy Tong; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

8.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

Authors:  Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; Julie M Decker; Brandon F Keele; Jesus F Salazar-Gonzalez; Truman Grayson; David T McPherson; Li-Hua Ping; Jeffrey A Anderson; Ronald Swanstrom; Carolyn Williamson; George M Shaw; Beatrice H Hahn
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

9.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

10.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.